droloxifene inn usan former developmental code names also known nonsteroidal selective estrogen receptor modulator serm triphenylethylene developed originally germany later japan treatment breast cancer osteoporosis men postmenopausal women cardiovascular disorders abandoned never reached phase ii phase iii clinical trials indications development discontinued drug found significantly less effective tamoxifen treatment breast cancer two phase iii clinical droloxifene analogue tamoxifen specifically said increased affinity estrogen reduced partial estrogen agonistic affinity droloxifene estrogen receptor ranges relative estradiol different comparison ranges tamoxifen droloxifene causes dosedependent decrease luteinizing hormone folliclestimulating hormone levels indicating antigonadotropic activity dosedependently increases sex hormonebinding globulin levels indicating estrogenic activity similarly tamoxifen droloxifene partial estrogenic effects unlike tamoxifen droloxifene produce dna adduct liver tumors httpsenwikipediaorgwikidroloxifene